Saturday 17 October 2026
Export KMTS’s income statement to Excel — free account
Kestra Medical Technologies, Ltd.
KMTS Healthcare Medical Instruments & Supplies
Kestra Medical Technologies, Ltd.’s revenue for fiscal 2026 (year ended April 2026) was $95.1 million, up 59.0% from fiscal 2025. In the quarter to July 2026, revenue grew 59.9%, EPS fell 50.0%, free cash flow fell 17.8% and total debt rose 74.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
27.24
1.44
−5.02%
Follow KMTS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to April
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 13.25 | 17.34 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 30.00 | 29.66 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 300 | 330 | 443 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.09 | 0.18 | 0.21 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 28 | 60 | 95 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 1.30 | 40.47 | 51.37 | |||||
| EBT | — | — | — | — | — | — | — | (94) | (114) | (131) | |||||
| EBT margin, % | — | — | — | — | — | — | — | (338.30) | (190.05) | (138.05) | |||||
| Net income | — | — | — | — | — | — | — | (94) | (114) | (132) | |||||
| Depreciation | — | — | — | — | — | — | — | 12 | 9 | 10 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 1.40 | 2.43 | 1.76 | ||||
| Earnings | — | — | — | — | — | — | — | (4.73) | (5.13) | (2.43) | |||||
| Cash flow | — | — | — | — | — | — | — | (3.63) | (3.16) | (1.51) | |||||
| Capex | — | — | — | — | — | — | — | (0.61) | (0.95) | (0.65) | |||||
| Free cash flow | — | — | — | — | — | — | — | (4.25) | (4.10) | (2.16) | |||||
| Book value | — | — | — | — | — | — | — | (1.62) | 8.36 | 4.79 | |||||
| Shares, m | — | — | — | — | — | — | — | 20 | 25 | 54 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 9.89 | 11.80 | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 2.88 | 4.32 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 6.60 | 10.19 | |||||
| EV/FCF | — | — | — | — | — | — | — | (3.04) | (3.91) | (8.29) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (72) | (78) | (82) | ||||
| Capex | — | — | — | — | — | — | — | (12) | (23) | (35) | |||||
| Free cash flow | — | — | — | — | — | — | — | (84) | (101) | (117) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (18) | 217 | 172 | ||||
| Total debt | — | — | — | — | — | — | — | 43 | 41 | 43 | |||||
| Net debt | — | — | — | — | — | — | — | 34 | (196) | (154) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (32) | 205 | 260 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (73.83) | (40.24) | ||||
| ROIC | — | — | — | — | — | — | — | (2,631.90) | (746.28) | (79.54) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 6,352.81 | (56.60) | |||||
Negative figures in brackets.
Fiscal years to Apr 2026 · latest quarter Jul 2026 · fundamentals updated 2 Oct 2026
Charts ten years each
Kestra Medical Technologies, Ltd. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NVST Envista Holdings Corporation | $3.8B | 38.8× | 24.4× | +7.10% (above 0%: growing) | +106.25% (above 0%: growing) | +37.57% (above 0%: growing) | 55.72% | 10.99% | Compare |
| PLSE Pulse Biosciences, Inc | $3.3B | — (loss-making) | — (loss-making) | +4,922.22% (above 0%: growing) | n/m | −45.39% (below 0%: shrinking) | 37.10% | (5,823.04%) | Compare |
| WRBY Warby Parker Inc. | $3.0B | 334× | 122× | +9.81% (above 0%: growing) | n/m | −71.75% (below 0%: shrinking) | 57.94% | 1.34% | Compare |
| ATRC AtriCure, Inc. | $2.9B | 259× | 591× | +12.83% (above 0%: growing) | n/m | −2.79% (below 0%: shrinking) | 77.23% | 6.29% | Compare |
| LMAT LeMaitre Vascular, Inc. | $1.9B | 27.9× | 31.5× | +9.57% (above 0%: growing) | +22.95% (above 0%: growing) | −27.95% (below 0%: shrinking) | 72.13% | 28.98% | Compare |
| XRAY DENTSPLY SIRONA Inc. | $1.8B | — (loss-making) | 27.0× | −4.06% (below 0%: shrinking) | n/m | +252.94% (above 0%: growing) | 54.90% | 9.13% | Compare |
| KMTS Kestra Medical Technologies, Ltd. | $1.7B | — (loss-making) | — (loss-making) | +59.88% (above 0%: growing) | n/m | −17.75% (below 0%: shrinking) | 56.50% | (121.59%) | |
| AZTA Azenta, Inc. | $1.6B | — (loss-making) | — (loss-making) | +12.04% (above 0%: growing) | n/m | −134.69% (below 0%: shrinking) | 44.89% | (2.59%) | Compare |
| STAA STAAR Surgical Company | $1.1B | 304× | 103× | +111.04% (above 0%: growing) | n/m | +166.10% (above 0%: growing) | 74.55% | 10.80% | Compare |
| Median of peers | $2.4B | 259× | 67.3× | +10.93% | — | −15.37% | 56.83% | 7.71% |
Kestra Medical Technologies, Ltd. (KMTS) key facts
- Strength: Kestra Medical Technologies, Ltd.’s revenue for fiscal 2026 (year ended April 2026) was $95.1 million, up 59.0% from fiscal 2025.
- Kestra Medical Technologies, Ltd. (KMTS) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, KMTS traded at $27.24, a market capitalization of $1.7 billion.
- Return on equity was −56.6% and debt-to-equity 0.33.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 3.87 (safe zone) for fiscal 2026.